Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
ALVOW
#9037
Alvotech Ordinary Shares
0.370
0
+5.71%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
+5.71%
Variazione Mensile
-32.76%
Variazione di 6 mesi
-69.17%
Variazione Annuale
-84.19%
Chiusura Precedente
0.350
0
Open
0.370
0
Bid
Ask
Low
0.370
0
High
0.370
0
Volume
3
Mercati
Mercato Azionario Statunitense
Salute
ALVOW
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
TTM
Key stats
Total common shares outstanding
248.65 M
266.82 M
301.81 M
—
Valuation ratios
Enterprise value
—
—
—
—
Price to earnings ratio
—
—
—
—
Price to sales ratio
—
—
—
—
Price to cash flow ratio
—
—
—
—
Price to book ratio
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
0.62
0.58
0.19
—
Return on equity %
0.91
0.59
0.56
—
Return on invested capital %
—
—
—
—
Gross margin %
24.61
-72.26
32.8
—
Operating margin %
407.5
380.01
25.25
—
EBITDA margin %
—
—
—
—
Net margin %
604.09
590.83
84.08
—
Liquidity ratios
Quick ratio
0.95
0.46
1.69
—
Current ratio
1.38
0.75
2.35
—
Inventory turnover
0.9
2.2
1.83
—
Asset turnover
0.1
0.11
0.25
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
—
—
—
—
Net current asset value per share
—
—
—
—
Tangible book value per share
—
—
—
—
Working capital per share
—
—
—
—
Book value per share
—
—
—
—
Notizie
Alvotech: Why FDA Delays Don't Break The Bull Case (NASDAQ:ALVO)
Teva Pharmaceuticals: Why It’s Time To Cash Out (Downgrade) (NYSE:TEVA)
Alvotech: Initiating With Hold Rating On FDA CRL AVT05 And Reduced EBITDA Guidance (ALVO)
Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again (NYSE:JNJ)
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Alvotech (ALVO) Presents at Morgan Stanley 23rd Annual Global
Alvotech 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:ALVO)
Alvotech (ALVO) Q2 2025 Earnings Call Transcript
Johnson & Johnson Stock Just Proved The Bears Wrong Again (NYSE:JNJ)
Alvotech (ALVO) Q4 2024 Earnings Call Transcript
Why Organon Is A Top Pick For Income Investors (NYSE:OGN)